216 related articles for article (PubMed ID: 17325225)
21. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
Balashov SV; Park S; Perlin DS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2058-63. PubMed ID: 16723566
[TBL] [Abstract][Full Text] [Related]
22. Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility.
Dudiuk C; Macedo D; Leonardelli F; Theill L; Cabeza MS; Gamarra S; Garcia-Effron G
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242659
[No Abstract] [Full Text] [Related]
23. In vitro interaction of micafungin and fluconazole against Candida.
Rodríguez MM; Ruiz M; Pastor FJ; Quindós G; Carrillo A; Guarro J
J Antimicrob Chemother; 2007 Jul; 60(1):188-90. PubMed ID: 17525050
[No Abstract] [Full Text] [Related]
24. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
25. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins.
Hori Y; Shibuya K
Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909
[TBL] [Abstract][Full Text] [Related]
26. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
[TBL] [Abstract][Full Text] [Related]
28. Resistance to echinocandin-class antifungal drugs.
Perlin DS
Drug Resist Updat; 2007 Jun; 10(3):121-30. PubMed ID: 17569573
[TBL] [Abstract][Full Text] [Related]
29. Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.
Lockhart SR; Pham CD; Kuykendall RJ; Bolden CB; Cleveland AA
Diagn Microbiol Infect Dis; 2016 Jan; 84(1):52-54. PubMed ID: 26429293
[TBL] [Abstract][Full Text] [Related]
30. Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.
Forastiero A; Garcia-Gil V; Rivero-Menendez O; Garcia-Rubio R; Monteiro MC; Alastruey-Izquierdo A; Jordan R; Agorio I; Mellado E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6975-82. PubMed ID: 26324281
[TBL] [Abstract][Full Text] [Related]
31. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
32. Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.
Jensen RH; Justesen US; Rewes A; Perlin DS; Arendrup MC
Antimicrob Agents Chemother; 2014 Jun; 58(6):3550-2. PubMed ID: 24687511
[TBL] [Abstract][Full Text] [Related]
33. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
Zeidler U; Bougnoux ME; Lupan A; Helynck O; Doyen A; Garcia Z; Sertour N; Clavaud C; Munier-Lehmann H; Saveanu C; d'Enfert C
J Antimicrob Chemother; 2013 Jun; 68(6):1285-96. PubMed ID: 23378416
[TBL] [Abstract][Full Text] [Related]
34. Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.
Cantón E; Pemán J; Gobernado M; Alvarez E; Baquero F; Cisterna R; Gil J; Martín-Mazuelos E; Rubio C; Sánchez-Sousa A; Serrano C
Antimicrob Agents Chemother; 2005 Apr; 49(4):1604-7. PubMed ID: 15793151
[TBL] [Abstract][Full Text] [Related]
35. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.
Fekkar A; Meyer I; Brossas JY; Dannaoui E; Palous M; Uzunov M; Nguyen S; Leblond V; Mazier D; Datry A
Antimicrob Agents Chemother; 2013 May; 57(5):2380-2. PubMed ID: 23439642
[TBL] [Abstract][Full Text] [Related]
36. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method.
Pai MP; Jones AL; Mullen CK
Diagn Microbiol Infect Dis; 2007 May; 58(1):129-32. PubMed ID: 17240112
[TBL] [Abstract][Full Text] [Related]
37. Current perspectives on echinocandin class drugs.
Perlin DS
Future Microbiol; 2011 Apr; 6(4):441-57. PubMed ID: 21526945
[TBL] [Abstract][Full Text] [Related]
38. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
39. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
Moudgal V; Little T; Boikov D; Vazquez JA
Antimicrob Agents Chemother; 2005 Feb; 49(2):767-9. PubMed ID: 15673762
[TBL] [Abstract][Full Text] [Related]
40. Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.
Martí-Carrizosa M; Sánchez-Reus F; March F; Cantón E; Coll P
Antimicrob Agents Chemother; 2015; 59(6):3570-3. PubMed ID: 25779577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
